AREV — AREV Life Sciences Global Income Statement
0.000.00%
Last trade - 00:00Consumer DefensivesSpeculativeMicro Cap
Annual income statement for AREV Life Sciences Global, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.195 | 0.191 | 0.255 | 0.049 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.23 | 3.22 | 0.981 | 1.21 | 1.48 |
| Operating Profit | -8.23 | -3.02 | -0.79 | -0.958 | -1.43 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.27 | -3.19 | -1.05 | -0.99 | -1.44 |
| Net Income After Taxes | -8.27 | -3.19 | -1.05 | -0.99 | -1.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.27 | -3.19 | -1.05 | -0.99 | -1.44 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.27 | -3.19 | -1.05 | -0.99 | -1.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.286 | -0.362 | -0.059 | -0.087 | -0.047 |
| Dividends per Share |